H12O – CNIO Haematological Malignancies Clinical Research Unit
H12O – CNIO Haematological Malignancies Clinical Research Unit

Home | Research & Innovation | Scientific Programmes | Clinical Research Programme | H12O – CNIO Haematological Malignancies Clinical Research Unit

Staff Scientists

  • Santiago Barrio
  • Lucia Virginia Fernández
  • Miguel Gallardo
  • María Linares

Clinical Investigator

  • Rosa María Ayala
  • María Calbacho
  • Gonzalo Carreño
  • María Pilar Carreras
  • María Teresa Cedena
  • Francisco Javier De La Serna
  • Ana Jiménez
  • María Inmaculada Rapado
  • Antonia Rodríguez
  • Ricardo Sánchez

Post-Doctoral Fellows

  • Almudena García
  • Alejandra Leivas
  • Yanira Ruiz
  • Antonio Valeri
  • María Velasco

Graduate Students

  • Pedro Aguilar
  • Noemí Álvarez
  • Eva Castellano
  • Laura Córdoba
  • Jessica Encinas
  • Roberto García
  • Marta Ibáñez
  • Elena Maroto
  • Michael Ochieng
  • María Alejandra Ortiz
  • Alba Rodríguez
  • Laura Sánchez


  • Natalia Sofía Buenache
  • Sara Dorado
  • Adrián Fernández
  • Vanesa Garrido
  • Alicia Giménez
  • María Luz Morales
  • Laura Moreno
  • Miguel Ángel Navarro
  • Juan Manuel Rosa
  • Laura Rufián

Recently, the field of haematology has been gaining traction in cancer research, not only for the study of critical disease affecting human health, but also for its implications in solid cancers and the applicability of haematological tools to other areas.

In terms of cancer implications, immune cells play a remarkable role in metastasis, inflammation, and immune surveillance. In fact, this concept triggered the development of the most promising cancer therapy of the 21st century, immunotherapy.

Moreover, the haematology research area has been developing cutting-edge applications such as liquid biopsy, an easy peripheral blood/plasma analysis that can anticipate the appearance of disease, or the emergence of tumour clones in relapsed patients.

The following main lines of research define our laboratory:

  • Liquid biopsy, minimal residual disease, and next-generation sequencing.
  • Immunotherapy: NK/T-CAR, BITES and immune checkpoints in haematological and paediatric cancers.
  • Role of hnRNP K, master regulator of tumourigenesis.
  • Viral infection and cancer.